Original Article

The Effect of L-Arginine Oral Supplementation on the Improvement of Cardiovascular Function and Pulmonary Artery Pressure in Patients with Major and Intermedia β-Thalassemia

Abstract

Background: Thalassemia is the most common inherited anemia in worldwide. Heart failure is the most common cause of mortality and morbidity in patients with major and intermedia β-thalassemia. This study aimed to evaluate the effect of oral administration of L-arginine on the improvement of systolic Pulmonary Artery Pressure (PAP) and cardiac function in patients with major and intermedia β-thalassemia.

Methods: This randomized clinical trial was done on 88 patients with β-thalassemia admitted to Ali Asghar Hospital, Tehran, Iran between 2020 and 2021. Echocardiography was performed for all the patients before the intervention. Afterwards, the patients were randomly divided into two groups of placebo and L-arginine. The patients underwent echocardiography after eight weeks and were compared with respect to the results.

Results: The mean blood transfusion interval was 20.21 d in the placebo group and 17.14 d in the L-arginine group (P=0.082). The results revealed no significant difference between the two groups regarding the mean levels of Hemoglobin (Hb) and ferritin, frequency of splenectomy. However, the mean PAP significantly decreased from 32.88 to 26.02 in the L-arginine group (P=0.009), but did not change in the placebo group. Nonetheless, no significant change was observed in the mean Ejection Fraction (EF) before and after L-arginine administration.

Conclusion: L-arginine administration prevented the increase of PAP and was effective in preventing cardiovascular disorders including increased systolic PAP in patients with major and intermedia B-thalassemia. However, the results have to be confirmed in further studies with larger sample sizes.

 

1. Nienhuis AW, Nathan DG (2012). Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harb Perspect Med, 2(12): a011726.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89(10): 1187-1193.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al (2006). Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107(9): 3733-3737.
4. Breuer W, Ermers MJ, Pootrakul P, et al (2001). Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood, 97(3): 792-798.
5. Thein SL (2013). The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med, 3(5): a011700.
6. Morris CR, Gladwin MT, Kato GJ, et al (2008). Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med, 8(7): 620-632.
7. El-Hady SB, Farahat MH, Atfy M, et al ( 2012 ). Nitric oxide metabolites and arginase I levels in β-thalassemic patients: an Egyptian study. Ann Hematol, 91(8): 1193-1200.
8. Nagaya N, Uematsu M, Oya H, et al (2001). Short-term oral administration of l-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med, 163(4): 887-891.
9. Lerman A, Burnett JC Jr, Higano ST, et al (1998). Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation, 97(21): 2123-2128.
10. Andrews DT, Sutherland J, Dawson P (2012). L-arginine cardioplegia reduces oxidative stress and preserves diastolic function in patients with low ejection fraction undergoing coronary artery surgery. Anaesth Intensive Care, 40(1): 99-106.
11. Morris CR (2006). New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. Treat Respir Med, 5(1): 31-45.
12. Kaye DM, Parnell MM, Ahlers BA (2002). Reduced myocardial and systemic l-arginine uptake in heart failure. Circ Res, 91(12): 1198-1203.
13. Orozco-Gutiérrez JJ, Castillo-Martínez L, Orea-Tejeda A, et al (2010). Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J, 17(6): 612-618.
14. Salmani M, Alipoor E, Navid H, et al (2021). Effect of l-arginine on cardiac reverse remodeling and quality of life in patients with heart failure. Clin Nutr, 40(5): 3037-3044.
15. Schulman SP, Becker LC, Kass DA, et al (2006). L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. JAMA, 295(1): 58-64.
16. Ahmed El-Masry HM, El-Shanshory MR, Ali Hassan Mahmoud AE, et al (2020). Comparative therapeutic effect of the l-arginine and sildenafil on beta-thalassemia children with increased tricuspid regurgitant jet velocity. J Pediatr Hematol Oncol, 5(2): 25-29.
Files
IssueVol 52 No 5 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i5.12721
Keywords
Beta-thalassemia L-arginine Systolic pulmonary artery pressure Ejection fraction Cardiovascular function
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ansari Damavandi S, Parsaee M, Ahmadi Marzaleh M, Shamspour M. The Effect of L-Arginine Oral Supplementation on the Improvement of Cardiovascular Function and Pulmonary Artery Pressure in Patients with Major and Intermedia β-Thalassemia. Iran J Public Health. 2023;52(5):1031-1037.